ARTICLE | Emerging Company Profile

Progressive play

Medday's MD 1003 could reverse disease progression in advanced MS

November 24, 2014 8:00 AM UTC

Medday S.A.S. is developing MD 1003, a concentrated formulation of D-biotin that targets a rate-limiting enzyme in myelination and could stop disease progression in advanced multiple sclerosis. Proof could come with Phase III data early next year.

D-biotin is an FDA-approved food additive. However, the daily dosage of MD 1003 is about 10,000 times the recommended daily dose of the food additive. Medday has U.S. patents covering the method of use for high-dose D-biotin in MS. An application for the formulation has been filed...